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ABSTRACT Despite recent improvements, α1-antitrypsin deficiency (AATD) remains a rarely diagnosed
and treated condition. To assess the variability of AATD diagnosis/treatment in Europe, and to evaluate
clinicians’ views on methods to optimise management, specialist AATD clinicians were invited to complete
a web-based survey.
Surveys were completed by 15 physicians from 14 centres in 13 European countries. All respondents
perceived the AATD diagnosis rate to be low in their country; 77% of physicians believed that ∼15% of
cases were diagnosed. Low awareness was perceived as the greatest barrier to diagnosis. Spirometry was
considered more practical than quantitative computed tomography (QCT) for monitoring AATD patients in
clinical practice; QCT was considered more useful in trials. AAT therapy provision was reported to be highly
variable: France and Germany were reported to treat the highest proportion (∼60%) of diagnosed patients,
in contrast to the UK and Hungary, where virtually no patients receive AAT therapy. Most clinicians
supported self-administration and extended dosing intervals to improve convenience of AAT therapy.
This survey indicates that AATD diagnosis and management are highly heterogeneous in Europe;
European cooperation is essential to generate data to support access to AAT therapy. Improving
convenience of AAT therapy is an ongoing objective.
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Introduction
α1-Antitrypsin deficiency (AATD) is a well-established, but underdiagnosed inherited condition that can
lead to emphysema and liver disease. It is caused by mutations in the SERPINA1 gene encoding
α1-antitrypsin (AAT), a key serum protease inhibitor. In individuals with AATD, serine proteases,
primarily neutrophil elastase, are not inhibited, resulting in degradation of lung tissue and eventual
progression to emphysema [1]. In addition, patients with the Z variant or rare variants such as MMalton or
Siiyam have an increased risk of developing liver disease, owing to protein accumulation in hepatocytes [1].
Multiple factors contribute to the underdiagnosis of AATD, including similarities in presentation to
general chronic obstructive pulmonary disease (COPD) and asthma and lack of access to testing, with low
disease awareness perhaps the key issue [2–5]. Targeted detection programmes aimed at symptomatic
individuals, e.g. COPD patients, and neonatal screening have been employed in Europe and have helped to
increase diagnosis rates [6–8]. However, active screening programmes for AATD do not exist in many
countries and numerous patients in Europe remain undiagnosed. Due to the progressive and irreversible
destruction of lung architecture in AATD, early detection is essential to enable lifestyle modifications
(e.g. smoking cessation) and appropriate treatment [9].
COPD related to AATD is managed symptomatically with bronchodilators [10], in line with
non-AATD-associated COPD. However, purified human AAT is the only disease-modifying therapy
currently available that can slow progression of emphysema related to AATD [11, 12]. Currently, the
therapy is recommended only for patients with severe deficiency genotypes, e.g. PI*ZZ (European
Respiratory Society (ERS) guidelines and US guidelines) and PI*SZ (US guidelines only) [13, 14]. The
optimal time for treatment initiation has been greatly debated. Recent US guidelines suggest that i.v. AAT
therapy can be considered in symptomatic individuals at any level of spirometric impairment, as
determined by forced expiratory volume in 1 s (FEV1) % predicted, although the strongest
recommendation for treatment is when FEV1 is ⩽65% pred [13]. The recent ERS statement does not
specify a threshold for treatment [14]. The 2003 statement from the American Thoracic Society (ATS) and
ERS recommended AAT therapy in patients with moderate airflow obstruction (e.g. FEV1 35–60% pred),
because historically there is more evidence of an effect on spirometric decline in this range [1].
Current trends are moving towards a personalised approach to AAT therapy provision [15], with
pharmacokinetic models demonstrating that extended dosing intervals are feasible [16]. Despite this, there
are few recommendations on methods to improve convenience of i.v. dosing regimens, e.g.
extended-interval dosing and self-administration. However, in many European countries, accessing AAT
therapy is the principal challenge – half the European countries surveyed in the latest ERS statement
reported having no access or very limited access to treatment [14].
To gain an understanding of the current status of AATD diagnosis and management in Europe, as well as
attitudes towards methods for AAT therapy optimisation, we performed a survey of European AATD experts.
Materials and methods
Data collection
Clinicians treating AATD from across Europe were invited to complete a web-based survey. The objective
was to gather expert opinion on the diagnosis and management of patients with AATD. The survey
consisted of 58 questions covering 1) size of patient population; 2) diagnosis and management of AATD;
3) AATD treatment options; 4) dosing of AAT therapy; and 5) self-administration and home treatment
with AAT therapy. Self-administration was defined as i.v. administration of AAT performed by the patient
or a non-professional (e.g. assistance from a spouse or relative). Home treatment was defined as i.v.
administration of AAT performed by a healthcare professional (e.g. physician or nurse).
Data analysis
Descriptive statistics only are reported; no formal statistical tests were performed.
Results
Survey representation
Completed surveys were returned by 15 physicians from 14 centres in 13 countries: Austria, Belgium, Czech
Republic, France, Germany, Hungary, Ireland, Italy, the Netherlands, Poland, Portugal, Spain and the UK.
All respondents are responsible for managing and treating patients with severe AATD genotypes, e.g. PI*ZZ.
Diagnosis of AATD
Physicians’ estimates of the number of diagnosed AATD cases varied greatly between countries and were
generally far lower than the number of individuals with severe AATD in each country based on published
estimates (table 1) [17, 18]. All respondents perceived the rate of diagnosis to be low in their countries:
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77% of physicians believed that ∼15% of cases had been diagnosed, with the remainder estimating a 30%
diagnosis rate. Few AATD screening programmes were reported in Europe (table 1); all respondents had
access to AAT serum level testing and phenotyping (isoelectric focusing), 93% had access to targeted
genotyping for common deficiency variants and 73% had access to SERPINA1 gene sequencing (to
identify rare/novel/null variants). The majority of physicians (60%) estimated that on average it took
⩾5 years to obtain a diagnosis of AATD from first onset of symptoms (figure 1a); lack of awareness was
most frequently cited as the biggest barrier to AATD diagnosis (77% of physicians) (figure 1b).
Treatment and monitoring of AATD
Across Europe, patients with AATD were reported to be symptomatically managed principally with
long-acting β-adrenergic receptor agonists, long-acting muscarinic receptor agonists and inhaled
corticosteroids. Provision of AAT therapy is highly variable throughout Europe. France and Germany were
reported to have the highest proportions of diagnosed AATD patients receiving AAT therapy (60%); in
Spain, ∼20% of patients receive treatment with AAT (figure 2).
TABLE 1 Testing for α1-antitrypsin deficiency (AATD) and the estimated number of cases in Europe
National AATD treatment infrastructure Estimated number of diagnosed AATD cases
versus overall number of severe deficiency carriers
Nationwide active
screening programme
Treatment centres
with >10 patients n
Estimated diagnosed
severe AATD cases n
Individuals with severe AATD genotype#
Based on
epidemiological
studies [17]
Mathematically
derived [18]
Austria No ⩾5 250 1435 (607–3318) 1529 (646–3536)
Belgium No 3 100 2896 (1583–5249) 2917
Czech Republic No 1 70 N/D N/D
France No ⩾5 ⩾1000 9982 (7662–12989) 17191 (13255–22270)
Germany No ⩾5 ⩾1000 8003 (5520–11577) 20611 (13380–31626)
Hungary Yes 0 ⩽50 458 (149–1352) N/D
Ireland Yes 0 300 N/D 2265 (1264–4019)
Italy No 1 500 15659 (2864–19150) 10652 (7046–16049)
The Netherlands No 1 500 1711 (976–2980) 5353 (3057–9298)
Poland Yes 1 100 662 (421–1039) 6791 (4395–10454)
Portugal No 3 150¶ 2005 (1054–3774) 4944 (2403–10004)
Spain Yes 4 650 12045 (7801–18522) 14522 (9405–22331)
UK No 3 2100 8588 (5906–12458)+ England: 11939
(7729–18360)
Scotland: 344
(182–644)
Data are presented as n (95% CI), unless otherwise stated. N/D: no data. #: PI*ZZ genotype only; ¶: averaged response from two respondents;
+: not including Wales.
2 years
3 years
4 years
Lack of awareness
Availability of
treatment
Other: lack of local
guidelines≥5 years
a) b)
6.7%
15.4%
7.7%
76.9%
20.0%
13.3%
60.0%
FIGURE 1 a) Estimated number of years to obtain formal diagnosis of α1-antitrypsin deficiency (AATD), from first onset of symptoms; b) barriers to
diagnosis of AATD in Europe.
https://doi.org/10.1183/23120541.00171-2018 3
COPD | I. HORVÁTH ET AL.
AAT therapy not reimbursed
AAT therapy partially reimbursed or with conditions
AAT therapy reimbursed
No information available
10%
25% 60%
30%
15%
50% 0%
40%
60%
35%
20%
0%
5%
Ireland: some patients on
compassionate-use programme
(Respreeza), but no general
reimbursement
The Netherlands: only
reimbursed in null/null and
null/Z patients in one
referral centre
Czech Republic and
Slovakia: only Respreeza
reimbursed
Belgium: only
reimbursed for
patients who
started therapy
before 2010
Alfalastin France
Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy,
the Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden and Switzerland
EU-wide
Product Countries with regulatory approval
Prolastin
Respreeza
FIGURE 2 α1-Antitrypsin (AAT) therapy availability across Europe. Reimbursement data obtained from European Respiratory Society 2017
statement [14]. Data are presented as percentage of diagnosed patients on AAT therapy; values based on individual physician estimates. Portugal
figure represents the average of two responses.
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AAT therapy considerations
Practical challenges with AAT infusions were reported, the most often cited being infusion time (33%;
figure 3a). The majority of respondents (73%) would consider alternative dosing strategies (e.g. bi-weekly
dosing); reasons included to cover holidays and for individuals in full-time employment. This practice is
already employed in some countries, e.g. all patients in the Czech Republic receive bi-weekly dosing, and it
is an option in France and Spain. Most respondents (87%) would consider providing AAT doses higher
than the recommended weekly dose of 60 mg·kg−1 in some situations, such as when the “protective
threshold” for AAT serum level was not reached, during exacerbations and for patients with rapidly
deteriorating disease. The main concern regarding higher doses was the lack of proven clinical efficacy;
however, nearly one-third of respondents (29%) had no concerns (figure 3b).
Monitoring of AATD
Physicians were asked what they perceived to be the most useful methods for monitoring disease
progression and treatment efficacy in diagnosed AATD patients (figure 4). Quantitative computed
tomography (QCT) of the lungs, i.e. measurement of lung density, was viewed as the most useful measure
in clinical trial settings. Diffusing capacity of the lung for carbon monoxide (DLCO) was considered the
most useful measure for monitoring AATD in routine clinical practice, but less useful in clinical trials.
Some physicians commented that DLCO can be very informative in trials involving fewer or single centres.
FEV1 was considered less useful than QCT and DLCO in trials, but more practical than QCT in routine
clinical practice.
Optimising treatment of AATD
Timing of treatment initiation
Most physicians surveyed would consider using AAT therapy in patients with moderate disease severity,
i.e. FEV1 <80% and ⩾35% pred (figure 5). A minority would consider AAT in early- and late-/end-stage
disease (FEV1 ⩾80% and <35% pred). Some physicians commented that in patients with severe AATD and
Large infusion volume
8.3%
a) b)
8.3%
33.3%
16.7%
16.7%
8.3%
8.3%
Lengthy infusion time
Available vial size
Other: frequency of infusions
Other: outpatient clinic
overbooked, difficult to schedule
Other: treatment provided by
one centre only
Other: the need for i.v. infusions
Clinical efficacy yet to be
demonstrated
Potential adverse effects with
higher doses
Insurance coverage/cost issues
No concerns
50.0%
60504030
Respondents %
20100
14.3%
35.7%
28.6%
FIGURE 3 α1-Antitrypsin (AAT) therapy considerations: a) practical difficulties with AAT infusions; b) concerns regarding AAT doses >60 mg·kg
−1
per week. Data are presented as percentage of respondents; physicians could choose more than one concern regarding AAT doses >60 mg·kg−1.
No AAT products were specified and there was no agreed definition on what constituted a lengthy infusion time.
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FIGURE 4 Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical
practice. FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide; QCT: quantitative computed tomography;
QoL: quality of life.
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FEV1 above the historically recommended range for treatment (FEV1 35–60% pred) [1], QCT should be
used to confirm the presence, severity and distribution of emphysema.
Self-administration
Self-administration of i.v. AAT was not available in any of the countries surveyed. However, all respondents
would consider self-administration for some patients if it were available. Respondents suggested that a
number of patient groups would benefit from self-administration, e.g. those in employment (figure 6a).
Overall, ∼50% of respondents felt that for patients to self-administer independently, three training sessions
would be required (figure 6b); 86% of respondents felt that training should be provided by hospital-based
respiratory nurses. Greater independence was viewed as the most important advantage of
self-administration; safety issues surrounding i.v. administration were viewed as the main disadvantage.
Home treatment
Home treatment was available in four of the countries surveyed (Ireland, France, Poland, Czech Republic),
provided by trained community nurses, but only as part of clinical trials in Ireland and Poland. Home
therapy is the only treatment option in Ireland and France; in Poland, regular treatment is provided at
home, but is also available at hospital outpatient clinics. Convenience for the patient was viewed as the
most important advantage of home treatment; fewer resources available in the event of an emergency was
most frequently cited as the main disadvantage.
Discussion
This survey of experienced clinicians treating AATD indicates that levels of diagnosis and disease awareness
in Europe remain low. Furthermore, there is great variability across Europe in the provision of AAT
therapy, the only pharmacological intervention able to slow emphysema progression related to AATD.
FIGURE 5 Degree of lung function
impairment at which physicians
would consider commencing α1-
antitrypsin therapy. FEV1: forced
expiratory volume in 1 s.
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“<50 years old,
full-time job, compliant”
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b)
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living a distance from the
hospital or a young
patient still in work”
“Young, working person
with poor access
to the hospital”
21.4%
28.6%
50.0%
“Patients without cognitive
impairment in work who
have the ability to work
cleanly and efficiently”
“An older, active patient,
potentially receiving
oxygen therapy”
“Young, active, mobile,
in employment,
with family”
2 3 ≥5
Ideal
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FIGURE 6 Physician perspectives on self-administration of i.v. α1-antitrypsin. a) The ideal candidate for self-administration; b) the number of
training sessions required for a patient to self-administer independently. Data are presented as percentage of respondents.
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Published reports [17, 18] provide high estimates of the number of PI*ZZ carriers in Europe; although
these do not reflect the number of symptomatic cases, the estimated numbers of diagnosed cases reported
in our survey are lower than might be expected. This disparity may be due to the number of patients who
are currently asymptomatic [19]; however, it is likely that many patients are misdiagnosed or face delays in
diagnosis [2, 4]. Most physicians surveyed believed that only 15% of AATD cases had been identified, and
that a confirmed diagnosis of AATD takes >5 years to obtain. A similar scenario was reported in Canada,
with a delay in diagnosis of 7 years [20]. Our survey suggests that low awareness remains the biggest
contributor to underdiagnosis/delay in diagnosis in Europe, consistent with previous studies [4, 5, 21]. In
Europe, an overarching issue is that awareness and detection in primary care are very low, with few
physicians referring patients for AATD testing [4, 21]. Nevertheless, there have been successes with public
health campaigns focused on improving diagnosis. For example, in Germany, a disease-awareness
campaign coupled with AATD testing dramatically improved AATD detection [6].
Although AATD screening programmes in Europe have helped to increase detection of AATD and
improve access to AAT therapy [7, 22–25], only four national screening programmes were reported in our
survey (table 1). There are several screening strategies for AATD, including population-based screening,
targeted screening of COPD patients, testing patients with liver disease and familial screening.
Population-based screening is uncommon and one of the few implementations of this approach was the
neonatal screening programme employed by Sweden in the 1970s. This programme provided important
insights into the natural history of AATD and the variability of presentation; in addition, awareness of the
condition enabled patients to avoid respiratory risk factors, e.g. smoking [7]. However, population-based
screening programmes can be prohibitively expensive and therefore their use has been limited to high-risk
areas, e.g. in remote/isolated communities [26]. Currently, targeted screening programmes are viewed as the
most feasible and economically viable approach [24], with these enriched populations leading to far higher
AATD detection rates [8]. Guidelines recommend that several respiratory conditions (e.g. emphysema,
bronchiectasis) and nonrespiratory conditions (e.g. liver disease, panniculitis) should trigger testing, and the
strongest universal recommendation is to test all newly diagnosed COPD patients [1, 13, 27, 28].
Furthermore, owing to Mendelian inheritance, familial screening provides the highest likelihood of
uncovering additional AATD cases. All guidelines advocate familial testing, with testing of siblings being
the highest priority [1, 13, 14]. Testing recommendations from guidelines/statements are outlined in table 2.
Regarding monitoring of disease progression in AATD, the recent ERS statement suggests that patients be
assessed regularly by a multidisciplinary team in the first year after diagnosis [14]. Our survey revealed
lung function testing via DLCO and FEV1 to be central to AATD monitoring in European clinics. This is
in line with available guidance (table 2) [1, 13]. A recommendation in guidelines from the US Alpha-1
Foundation is to conduct a baseline computed tomography (CT) scan as part of the initial assessment of
AATD patients [13]. The guidelines do not recommend serial CT scanning owing to the associated
radiation dosage and a lack of clarity on how best to use scan data for clinical management. Survey
respondents generally felt that QCT was more suited to studies in AATD, and less applicable in clinical
practice. Although lung densitometry by CT has been validated against lung pathology/function and
health status, and has been the main outcome measure in clinical trials of AAT therapy, there are practical
issues that reduce its applicability to routine practice [29]. Many centres do not have the requisite
equipment/software to routinely conduct lung density assessment [9]. However, lung density data from
clinical practice, such as that collated by the UK Antitrypsin Deficiency Assessment and Programme
for Treatment (ADAPT) registry [30], have been extremely useful for research purposes, and could help
to enhance the evidence base for AAT therapy. Regarding other approaches, some respondents indicated
that monitoring quality of life was beneficial. Data from a recent meta-analysis indicate a possibility that
AAT therapy has some efficacy on St George’s Respiratory Questionnaire (SGRQ), a commonly used
quality-of-life measure in respiratory disease [31]. However, this finding was associated with considerable
uncertainty and further studies are required.
One aim of our survey was to assess how and when physicians utilise AAT therapy. Currently, AAT
therapy is recommended only for symptomatic AATD patients, e.g. patients with airflow obstruction and
physiological signs of emphysema [1, 13]. The ATS/ERS statement from 2003 recommended that therapy
be utilised between a defined range of FEV1 deterioration (35–60% pred); however, today there is less
emphasis placed on FEV1 ranges, and the recent ERS statement does not refer to this as a criterion for
treatment [14]. Nonetheless, insurance coverage may still be linked to FEV1 deterioration, and most
physicians surveyed would not consider treatment at all levels of FEV1 decline. However, some
respondents would consider providing AAT in early-stage disease. Recent evidence provides a strong
rationale for early intervention in AATD: data from the RAPID clinical trial programme suggest improved
outcomes with early AAT therapy, with a discernible effect on lung density decline observed regardless of
baseline FEV1 [12, 32, 33].
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TABLE 2 Comparison of recommendations from American Thoracic Society (ATS)/European Respiratory Society (ERS)
guidelines (2003), US Alpha-1 Foundation guidelines (2016) and ERS statement (2017)
ATS/ERS statement (2003) [1] US Alpha-1 Foundation guidelines
(2016) [13]
ERS statement (2017) [14]
Diagnostic tests AAT serum levels should not be viewed
in isolation
Phenotyping or targeted genotyping may
be utilised
Phenotyping may be insufficient to detect
rare variants and sequencing may be
required
Targeted genotyping for S and Z alleles
as a minimum
Initial tests can be confirmed by
phenotyping, quantitation of AAT
serum levels and/or expanded
targeted genotyping
Establishing AAT serum levels is a
crucial first test, but must be
supported by qualitative evidence
of a mutation
Phenotyping and genotyping can both
be used to establish mutation(s)
present
Gene sequencing is necessary when
a null or rare variant is suspected
Who should be
tested?
Testing for index
case
Emphysema with early onset (<45 years)
or without recognised risk factors, e.g.
smoking, or with basilar hyperlucency
Bronchiectasis or liver disease with
unknown aetiology
Necrotising panniculitis and
anti-proteinase 3-positive vasculitis
Family history of emphysema,
bronchiectasis, panniculitis or liver
disease
COPD or unexplained bronchiectasis,
regardless of age/ethnicity
All individuals with liver disease of
unknown aetiology
All patients with granulomatosis with
polyangiitis/necrotizing panniculitis
COPD or adult-onset asthma
Familial testing Recommended for siblings of index
cases with severe deficiency
Should be discussed with offspring or
distant relatives of individuals with
severe deficiency, and siblings,
offspring, parents and distant relatives
of individuals with intermediate
deficiency
Parents, sibling, offspring and extended
family should be offered genetic
counselling and testing
AAT level testing alone is not
recommended when testing family
members
Test parents of index case only if a
null gene is suspected
Test partner of index case; if PI*MZ is
found, test offspring of index case
Test sibling(s) of index case; if PI*MZ
is found, test partner of sibling(s),
if further PI*MZ is found, test
offspring of sibling(s)
Population
screening
Screening of any age group should be
discouraged; screening of active
smokers with normal spirometry is
not recommended
Monitoring Full lung function testing at baseline and
spirometry at yearly intervals
Regular liver function testing requires
investigation
Baseline and annual spirometry
CT scan at baseline; serial CT scanning
not recommended
Monitor for liver disease annually: liver
ultrasound and AST, ALT, GGT,
albumin, bilirubin and INR
Importance of multidisciplinary
approach highlighted
Baseline: assess lung physiology and
conduct routine liver function and
blood tests
Up to 3 months: reassess and collate
data; monitor exacerbation diary,
initiate smoking cessation
Up to 6 months: assess full
physiology, QoL assessment,
routine blood tests
6–12 months: continue monitoring,
initiate AAT therapy as appropriate
FEV1 and DLCO are useful to monitor
disease progression
AAT therapy
utilisation
Recommended Symptomatic individuals with FEV1
35–65% pred
Symptomatic individuals with FEV1
⩽65% pred (strongest
recommendation); treatment can be
considered outside of this range
Symptomatic individuals (no FEV1
range given)
Not
recommended
PI*MZ individuals and current smokers PI*MZ and current smokers
Emphysema/ bronchiectasis without
airflow obstruction
PI*MZ, PI*SZ and current smokers
AAT: α1-antitrypsin; COPD: chronic obstructive pulmonary disease; CT: computed tomography; AST: aspartate aminotransferase; ALT: alanine
aminotransferase; GGT: γ-glutamyltransferase; INR: international normalised ratio; QoL: quality of life; FEV1: forced expiratory volume in 1 s;
DLCO: diffusing capacity of the lung for carbon monoxide
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The standard dose for AAT therapy is 60 mg·kg−1 per week; higher AAT doses are not currently licensed
or recommended. However, this survey indicates that some physicians would consider providing higher
doses, e.g. at times of exacerbation or for patients with fast-declining lung function. There is increasing
interest in higher AAT doses: a recent pilot study found that normalising serum AAT levels in AATD
patients by increasing dosing from 60 to 120 mg·kg−1 per week further reduced markers of residual
proteolytic and inflammatory activity [34]. In addition, an analysis of patients who received 120 mg·kg−1
AAT or placebo to cover 2-week periods in the RAPID clinical trial programme found no increase in the
infusion-adjusted event rate at 24 h and 72 h after administration [35]. The clinical utility and long-term
safety of higher doses require further study and trials are ongoing.
This survey highlights that access to AAT therapy is not uniform throughout Europe, with some countries
reporting that no diagnosed AATD patients receive AAT therapy. Indeed, the recent ERS statement
suggests that reimbursement is an ongoing challenge in Europe (figure 2) [14]. The European situation
reflects the Canadian experience, where large disparities in the provision of AAT therapy were observed
between provinces [20]. Within the European Union (EU), policies exist to support equal access to novel
therapies between countries. For example, directive 89/105/EEC6 states that pricing and reimbursement
decisions must be made in a timely and transparent manner [36]. Nevertheless, these decisions are
ultimately at the discretion of member states according to their independent appraisal of the technology
and budgetary requirements [37]. In addition, although EU polices support cross-border diagnosis and
treatment in rare diseases (EU directive 2011/24/EU), the health authority or insurance provider in the
home country must agree to reimburse treatment in the destination country [37]. This issue, coupled with
the impracticality of travelling abroad for medical treatment, suggests that cross-border treatment is not a
long-term solution to address variation in access to AAT therapy in Europe.
Continuing to build the evidence base for AAT therapy is essential to support access to treatment. The
RAPID clinical trial programme demonstrated that AAT therapy is effective and disease-modifying in
AATD [11, 12, 33]. Beyond this, some authorities desire data on patient-centred outcomes, e.g. mortality
and QoL, to support the pharmacoeconomic profile of AAT therapy [38]. However, it is difficult to
generate these data in clinical trials, as large numbers of AATD patients would have to be followed for
long durations. Patient registries in Europe are therefore crucial in gathering longitudinal data of the
efficacy of AAT therapy on these outcomes [14].
Where AAT therapy is available, improving convenience is a key challenge. Alternative dosing strategies
(e.g. bi-weekly) and home treatment are already used in some European countries [28, 39]. In addition to
the national home treatment programmes reported here, a third party-sponsored Berlin-based programme
in Germany has reported successful results in terms of improving patient monitoring and reducing
exacerbation-related hospitalisations in a small pilot study [40]. Self-administration is likely to be beneficial
for subsets of AATD patients and could help reduce costs associated with treatment. Self-administration
with increased intervals between infusions has been trialled in AATD and reduced the annual cost of AAT
therapy [41]. Furthermore, self-administration is performed safely in other disease areas, such as
haemophilia and immunoglobulin deficiencies [42, 43]. Overall, the physicians surveyed supported these
measures to help improve convenience for patients.
Limitations
Data were gathered from a survey of AATD experts and do not represent clinical findings. All data (unless
otherwise specified) are estimates based on individual physician experience, and do not necessarily reflect
actual regional policy and patient demographics. Nevertheless, all physicians selected for the survey were
experts in the field of AATD, and were thus well positioned to provide an overview of the status of AATD
diagnosis/management in their respective countries based on their clinical experience. Although a good
cross-section of Europe is represented, in most cases, only one expert physician from each country
returned a response. Further studies including more responses from each country would be required to
verify the data.
Conclusions
This physician survey strongly indicates that AATD remains underdiagnosed and undertreated in Europe.
More initiatives are required to support disease awareness and encourage screening of individuals with
COPD, adult-onset asthma or bronchiectasis and family members of diagnosed patients. The availability of
AAT therapy varies greatly between European countries; cooperation is essential to generate data that
could support access to treatment, and to raise awareness of successes in countries where the treatment is
available. Improving convenience of AAT therapy is an ongoing objective.
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